Latest News and Press Releases

DENVER, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company”), a biopharmaceutical company focused on the treatment of mental...

Dr. Matthew Johnson will lead research to look at the science and efficacy of MYCO-001 for the treatment of smoking cessation and nicotine dependence DENVER, Sept. 07, 2021 (GLOBE NEWSWIRE) --...

DENVER, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a clinical-stage biopharmaceutical company aiming to...

DENVER, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), is pleased to announce that it has filed and mailed its management...

DENVER, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) announces it has signed a five-year research agreement with Johns Hopkins University (JHU) School of...

Groundbreaking Progress in Clinical Trial and Drug Discovery Programs Enhanced Technology Offering with Mindleap 2.0, its Digital Health Platform to Support the Adoption of Psychedelics into Mental...

DENVER, July 28, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...

DENVER, July 21, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to...

The digital health platform will provide the infrastructure to support the conscious and trustworthy adoption of psychedelics DENVER, July 13, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group...

DENVER, June 24, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...